Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / AFP



This biomarker is also known as:
  • OTTHUMP00000160480,
  • HPAFP,
  • Alpha-fetoglobulin,
  • HP,
  • FETA,
  • Alpha-1-fetoprotein,
  • Alpha-fetoprotein,

View in BioMuta


AFP is a major plasma protein produced by the yolk sac and the liver during fetal life. Alpha-fetoprotein expression in adults is often associated with hepatoma or teratoma. However, hereditary persistance of alpha-fetoprotein may also be found in individuals with no obvious pathology. The protein is thought to be the fetal counterpart of serum albumin, and the alpha-fetoprotein and albumin genes are present in tandem in the same transcriptional orientation on chromosome 4. Alpha-fetoprotein is found in monomeric as well as dimeric and trimeric forms, and binds copper, nickel, fatty acids and bilirubin.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


Performance Comment

AFP is not being further evaluated as a biomarker for breast cancer at this time.



Phase: Three
QA State: Under Review


Since 90% of patients with hepatocellular carcinoma (HCC) have underlying cirrhosis, patients with cirrhosis are candidates for HCC surveillance. Despite advances in medical technology, the 5-year survival of patients with HCC has improved minimally from 2% to 5% from 1981 to 1998. This may be largely due to diagnosis at late stage disease. These studies aim to compare the performance characteristics of the biomarkers AFP, DCP (des-gamma carboxyprothrombin) and AFP-L3 (lectin-bound AFP) in the early diagnosis of HCC.

Performance Comment

AFP has been approved by the FDA as a component of lab test to diagnose the risk of developing liver cancer in patients with chronic liver disease (CLD). The test measures levels of both AFP-L3 and AFP in the blood, and calculates AFP-L3 levels as a percentage of total AFP. Higher levels of AFP-L3 are associated with higher risk of developing liver cancer. According to the FDA, if the percentage of AFP-L3 is greater or equal to 10%, the risk is seven-fold that the patient will develop liver cancer in the next 21 months.



Phase: Three
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.